Status:
UNKNOWN
Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial
Lead Sponsor:
Yonsei University
Conditions:
Coronary Artery Disease, Acute Coronary Syndrome
Eligibility:
All Genders
19-80 years
Phase:
NA
Brief Summary
We hypothesized that ticagrelor monotherapy might be enough to prevent thromboembolic events without aspirin after PCI in patients with acute coronary syndrome(ACS). Moreover, ticagrelor monotherapy w...
Eligibility Criteria
Inclusion
- Patients ≥19 years old
- Patients who received new generation sirolimus-eluting (Orsiro® series) stent implantation for treating ACS, including acute MI and unstable angina
- Provision of informed consent
Exclusion
- Age\> 80 years
- Increased risk of bleeding, anemia, thrombocytopenia
- A need for oral anticoagulation therapy
- Pregnant women or women with potential childbearing
- Life expectancy \< 1 year
Key Trial Info
Start Date :
April 24 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 4 2025
Estimated Enrollment :
2850 Patients enrolled
Trial Details
Trial ID
NCT03797651
Start Date
April 24 2019
End Date
April 4 2025
Last Update
March 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine
Seoul, South Korea, 03722